



12 October 2026

National Stock Exchange of India Limited
NSE Code: SUNPHARMA

BSE Limited
BSE Code: 524715

Outcome of the Board Meeting held today, i.e., 12 October 2026

Further to the communication dated [07 October 2026](#), this is to inform that the meeting of the Board of Directors of the Company ("Board") was held today, i.e. 12 October 2026, which commenced at 05:00 P.M. and concluded at 05:50 P.M., IST. The Board, inter alia, considered and approved the following:

1. Issuance of Non-Convertible Debentures

The Board of Directors has approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures ("NCDs"), on a private placement basis, in one or more tranches and/or series, for an aggregate amount not exceeding INR 10,000 Crore.

The Board has also approved the related issuance framework and authorised the Finance Committee to determine and approve the tranche-specific terms and conditions of the NCDs, including matters relating to their issuance, allocation and allotment, within the framework approved by the Board.

The disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be made at the appropriate stage, upon issuance and/or allotment of the NCDs.

2. Resignation of Mr. Gautam Doshi

Mr. Gautam Doshi (DIN: 00004612) has tendered his resignation as a Non-Executive, Independent Director of the Company with effect from 12 October 2026, citing personal reasons. He has confirmed that there are no material reasons for his resignation other than those stated in his resignation letter. Consequent upon his resignation, he has also ceased to hold positions on the Committees of the Board of Directors of the Company.

The Board of Directors has taken note of the resignation of Mr. Gautam Doshi and placed on record its sincere appreciation for the valuable guidance and contributions made by him during his tenure as an Independent Director of the Company.

The details required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in [Annexure A](#) and the resignation letter of Mr. Gautam Doshi is enclosed herewith as [Annexure B](#).

For Sun Pharmaceutical Industries Limited

Anoop Anjanikumar
Deshpande
Digitally signed by Anoop
Anjanikumar Deshpande
Date: 2026.10.12 19:48:29
+05'30'

(Anoop Deshpande)

Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	
1	Name	Mr. Gautam Doshi (DIN: 00004612)
2	Reason for change viz. resignation	Resignation from the position of Non-Executive Independent Director of the Company with immediate effect due to his personal commitments.
3	Date of cessation	12 October 2026
4	Brief profile (in case of appointment);	Not Applicable
5	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
6	Letter of resignation along with detailed reason for resignation	Enclosed as Annexure B
7.	Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any	Not Applicable
8.	The independent director shall, along with the detailed reasons, also provide a confirmation that there are no other material reasons other than those provided	Mr. Gautam Doshi confirmed that there are no material reasons for his resignation other than those mentioned in her resignation letter.

C. RASHMIKANT
VISHESH MALVIYA
NIKITA MISHRA

S. R. DAKSHINI
POOJA KOTHARI
PRAKHAR PAREKH

ROHAN DAKSHINI
SHWETA JAYDEV
NAMRATA SHAH



REF NO: RNP/2052/2026

12th October 2026

To,

Anoop Deshpande
Company Secretary and Compliance Officer
Sun Pharmaceutical Industries Limited

Subject: Resignation from the office of Independent Director – Mr. Gautam Doshi

Dear Anoop,

Mr. Gautam Doshi, our client who is serving as an Independent Director on the Board of Sun Pharmaceutical Industries Limited and some of its subsidiaries has instructed us to communicate the following to you due to his inability to send this communication on account of circumstances beyond his control.

“Dear Members of the Board,

I would like to step down from the position as an Independent Director on the Board of Directors of Sun Pharmaceutical Industries Limited, due to personal reasons and request you to accept my resignation with immediate effect.

Consequently, I also resign from all Committees of the Board of the Company of which I am a member, as well as from all directorships, committee memberships and other positions, held by me in the subsidiary companies of Sun Pharmaceutical Industries Limited viz., Sun Pharma Laboratories Limited; Sun Pharma Holdings, Mauritius; Sun Pharmaceutical Industries, Inc., USA; and Taro Pharmaceuticals U.S.A., Inc. USA, with immediate effect.

I confirm that there are no material reasons for my resignation other than those stated above.

I request the Board and the respective companies to take note of my resignation and complete the necessary filings, disclosures and other consequential compliances required under applicable law.

It has been a pleasure and privilege to serve as an Independent Director on the Board of India's largest pharmaceutical company, an Indian multinational. I thank all the colleagues on the Board and the management for their support and cooperation during my association with the Company and convey my best wishes for the Company's continued success.

Gautam Doshi
DIN: 00004612”

Yours faithfully,
For Rashmikant and Partners

Partner